Artificial polypeptide LH, antibody thereof and application in pathological detection
An artificial and pathological technology, applied in the fields of biological detection and immunology, can solve the problems of no obvious reduction in polymer steric hindrance, no significant increase in the number of antibodies, and many toxic and harmful chemical reagents. Good reproducibility and reproducibility, and the effect of improving sensitivity and specificity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0068] Example 1 Preparation of Enhanced Secondary Antibody System Using Artificial Peptides
[0069] This example provides a method for preparing an enhanced secondary antibody using an artificial polypeptide and its application in pathological detection.
[0070] First, artificial polypeptides are prepared. The artificial polypeptide sequences are completely artificially designed and synthesized. The design principle is: the sequences that do not naturally exist in mammals, and the antibodies produced by them have no specific cross-reaction with mammals, especially with proteins on human tissues. .
[0071] Secondly, prepare a polyclonal antibody against the primary antibody and couple it with an artificial polypeptide to form an artificial polypeptide-antibody conjugate, that is, the post-primary antibody reagent. A polyclonal antibody can be conjugated to multiple artificial polypeptides to amplify the detection signal.
[0072] Then, prepare the anti-artificial polypept...
Embodiment 2
[0084] Embodiment 2 artificial polypeptide
[0085] The artificial polypeptide involved in this embodiment refers to a polypeptide that does not naturally exist in mammals, especially in human tissues.
[0086] Artificial polypeptide PL: the amino acid sequence is TTT(PTT)n, n=1~10, namely:
[0087] TTTPTT (SEQ ID NO: 1),
[0088] TTTPTTPTT (SEQ ID NO: 2),
[0089] TTTPTTPTTPTT (SEQ ID NO: 3),
[0090] TTTPTTPTTPTTPTT (SEQ ID NO: 4),
[0091] TTTPTTPTTPTTPTTPTT (SEQ ID NO: 5),
[0092] TTTPTTPTTPTTPTTPTTPTT (SEQ ID NO: 6),
[0093] TTTPTTPTTPTTPTTPTTPTTPTT (SEQ ID NO: 7),
[0094] TTTPTTPTTPTTPTTPTTPTTPTTPTT (SEQ ID NO: 8),
[0095] TTTPTTPTTPTTPTTPTTPTPTTPTTPTTPTT (SEQ ID NO: 9), or
[0096] TTTPTTPTTPTTPTTPTTPTTPTTPTTPTTPTT (SEQ ID NO: 10),
[0097] In order to facilitate protein coupling, a cysteine (C) can be added at the N-terminal or C-terminal of this amino acid.
[0098] Artificial polypeptide HM: the amino acid sequence is AAP(AADAAD)nAAPAAA, n=1~10, that ...
Embodiment 3
[0122] Embodiment 3 Preparation of Anti-artificial Polypeptide Antibody
[0123] Rabbits were immunized with the artificial polypeptide PL (TTTPTTPTT) in Example 2 to further prepare rabbit-derived monoclonal antibodies. The antibody can specifically bind to the artificial polypeptide PL, and the ELISA binding curve is shown in figure 2 , EC50 was 9.94ng / mL.
[0124] The anti-artificial polypeptide PL antibody was analyzed using Kabat online software, and the results showed that the variable region sequence of the antibody had the following information:
[0125] (1) The amino acid sequence of CDR-H1 includes: TNAMS (SEQ ID NO: 31).
[0126] (2) The amino acid sequence of CDR-H2 includes: IISSSGSTYYARWAKG (SEQ ID NO: 32).
[0127] (3) The amino acid sequence of CDR-H3 includes: GNI (SEQ ID NO: 33).
[0128] (4) The amino acid sequence of CDR-L1 includes: QSSQSVYNNNLA (SEQ ID NO: 34).
[0129] (5) CDR-L2 amino acid sequence includes: RASKLAS (SEQ ID NO: 35).
[0130] (6) ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


